PAGE 1
WES MOORE, Governor Ch. 217

Chapter 217

(House Bill 382)

AN ACT concerning

~~Pharmacy~~ ~~Benefits~~ ~~Administration~~ ~~–~~ ~~Maryland~~ ~~Medical~~ ~~Assistance~~ ~~Program~~ ~~and~~
~~Pharmacy~~ ~~Benefits~~ ~~Managers~~
Maryland Department of Health and Prescription Drug Affordability Board –
Managed Care Organizations and Prescription Drug Claims – Study

FOR the purpose of ~~altering~~ ~~the~~ ~~reimbursement~~ ~~levels~~ ~~for~~ ~~drug~~ ~~products~~ ~~that~~ ~~the~~ ~~Maryland~~
~~Medical~~ ~~Assistance~~ ~~Program~~ ~~is~~ ~~required~~ ~~to~~ ~~establish~~ ~~and~~ ~~that~~ ~~pharmacy~~ ~~benefits~~
~~managers~~ ~~that~~ ~~contract~~ ~~with~~ ~~a~~ ~~pharmacy~~ ~~on~~ ~~behalf~~ ~~of~~ ~~a~~ ~~managed~~ ~~care~~ ~~organization~~
~~are~~ ~~required~~ ~~to~~ ~~reimburse~~ ~~the~~ ~~pharmacy;~~ ~~altering~~ ~~the~~ ~~definition~~ ~~of~~ ~~“purchaser”~~ ~~for~~
~~purposes~~ ~~of~~ ~~certain~~ ~~provisions~~ ~~of~~ ~~law~~ ~~regulating~~ ~~pharmacy~~ ~~benefits~~ ~~managers~~ ~~to~~
~~include~~ ~~certain~~ ~~insurers,~~ ~~nonprofit~~ ~~health~~ ~~services~~ ~~plans,~~ ~~and~~ ~~health~~ ~~maintenance~~
~~organizations~~ requiring the Maryland Department of Health and the Prescription
Drug Affordability Board jointly to study certain information regarding the payment
of prescription drug claims under the Maryland Medical Assistance Program during
certain calendar years and how to address certain inconsistencies; and generally
relating to ~~pharmacy~~ ~~benefits~~ ~~administration~~ managed care organizations and the
payment of prescription drug claims.

~~BY~~ ~~repealing~~ ~~and~~ ~~reenacting,~~ ~~with~~ ~~amendments,~~
~~Article~~ ~~–~~ ~~Health~~ ~~–~~ ~~General~~
~~Section~~ ~~15–118(b)~~
~~Annotated~~ ~~Code~~ ~~of~~ ~~Maryland~~
~~(2019~~ ~~Replacement~~ ~~Volume~~ ~~and~~ ~~2022~~ ~~Supplement)~~

~~BY~~ ~~adding~~ ~~to~~
~~Article~~ ~~–~~ ~~Health~~ ~~–~~ ~~General~~
~~Section~~ ~~15–118(f)~~
~~Annotated~~ ~~Code~~ ~~of~~ ~~Maryland~~
~~(2019~~ ~~Replacement~~ ~~Volume~~ ~~and~~ ~~2022~~ ~~Supplement)~~

~~BY~~ ~~repealing~~ ~~and~~ ~~reenacting,~~ ~~with~~ ~~amendments,~~
~~Article~~ ~~–~~ ~~Insurance~~
~~Section~~ ~~15–1601(s)~~
~~Annotated~~ ~~Code~~ ~~of~~ ~~Maryland~~
~~(2017~~ ~~Replacement~~ ~~Volume~~ ~~and~~ ~~2022~~ ~~Supplement)~~

~~BY~~ ~~adding~~ ~~to~~
~~Article~~ ~~–~~ ~~Insurance~~
~~Section~~ ~~15–1632~~
~~Annotated~~ ~~Code~~ ~~of~~ ~~Maryland~~
~~(2017~~ ~~Replacement~~ ~~Volume~~ ~~and~~ ~~2022~~ ~~Supplement)~~
– 1 –

PAGE 2
Ch. 217 2023 LAWS OF MARYLAND

SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
That ~~the~~ ~~Laws~~ ~~of~~ ~~Maryland~~ ~~read~~ ~~as~~ ~~follows:~~

~~Article~~ ~~–~~ ~~Health~~ ~~–~~ ~~General~~

~~15–118.~~

~~[Except]~~ ~~SUBJECT~~ ~~(2)~~~~(b)~~ ~~(1)~~ ~~TO~~ ~~PARAGRAPH~~ ~~OF~~ ~~THIS~~ ~~SUBSECTION~~ ~~AND~~
~~[(2)]~~ ~~(3)~~~~as~~ ~~provided~~ ~~under~~ ~~paragraph~~ ~~of~~ ~~this~~ ~~subsection,~~ ~~the~~ ~~Program~~ ~~shall~~~~EXCEPT~~
~~[maximum]~~~~establish~~ ~~reimbursement~~ ~~levels~~ ~~for~~ ~~the~~ ~~drug~~ ~~products~~ ~~for~~ ~~which~~ ~~there~~ ~~is~~ ~~a~~
~~Article[,~~~~generic~~ ~~equivalent~~ ~~authorized~~ ~~under~~ ~~§~~ ~~12–504~~ ~~of~~ ~~the~~ ~~Health~~ ~~Occupations~~ ~~based~~ ~~on~~
~~product].~~~~the~~ ~~cost~~ ~~of~~ ~~the~~ ~~generic~~

~~(2)~~ ~~EXCEPT~~ ~~(4)~~ ~~SUBSECTION,~~~~AS~~ ~~PROVIDED~~ ~~IN~~ ~~PARAGRAPH~~ ~~OF~~ ~~THIS~~
~~(1)~~~~MINIMUM~~ ~~REIMBURSEMENT~~ ~~LEVELS~~ ~~ESTABLISHED~~ ~~UNDER~~ ~~PARAGRAPH~~ ~~OF~~ ~~THIS~~
~~NATIONAL~~ ~~AVERAGE~~ ~~DRUG~~~~SUBSECTION~~ ~~SHALL~~ ~~BE~~ ~~AT~~ ~~LEAST~~ ~~EQUAL~~ ~~TO~~ ~~THE~~
~~ACQUISITION~~ ~~COST~~ ~~OF~~ ~~THE~~ ~~GENERIC~~ ~~PRODUCT~~ ~~PLUS~~ ~~THE~~
~~FEE–FOR–SERVICE~~ ~~PROFESSIONAL~~ ~~DISPENSING~~ ~~FEE~~ ~~DETERMINED~~ ~~BY~~ ~~THE~~
~~DEPARTMENT~~ ~~IN–STATE~~~~IN~~ ~~ACCORDANCE~~ ~~WITH~~ ~~THE~~ ~~MOST~~ ~~RECENT~~
~~COST–OF–DISPENSING~~ ~~SURVEY.~~

~~[(2)]~~ ~~(3)~~ ~~[If]~~ ~~EXCEPT~~ ~~(4)~~~~AS~~ ~~PROVIDED~~ ~~IN~~ ~~PARAGRAPH~~ ~~OF~~ ~~THIS~~
~~SUBSECTION,~~ ~~a~~ ~~prescriber~~ ~~directs~~ ~~a~~ ~~specific~~ ~~brand~~ ~~name~~ ~~drug,~~ ~~the~~ ~~reimbursement~~ ~~level~~~~IF~~
~~[cost]~~ ~~NATIONAL~~ ~~AVERAGE~~ ~~DRUG~~ ~~ACQUISITION~~ ~~COST~~~~shall~~ ~~be~~ ~~based~~ ~~on~~ ~~the~~ ~~of~~ ~~the~~
~~FEE–FOR–SERVICE~~~~brand~~ ~~name~~ ~~product~~ ~~PLUS~~ ~~THE~~ ~~PROFESSIONAL~~ ~~DISPENSING~~ ~~FEE~~
~~DEPARTMENT~~~~DETERMINED~~ ~~BY~~ ~~THE~~ ~~IN~~ ~~ACCORDANCE~~ ~~WITH~~ ~~THE~~ ~~MOST~~ ~~RECENT~~
~~IN–STATE~~ ~~COST–OF–DISPENSING~~ ~~SURVEY.~~

~~(4)~~ ~~PARAGRAPHS~~ ~~(2)~~ ~~(3)~~ ~~TO:~~~~AND~~ ~~OF~~ ~~THIS~~ ~~SUBSECTION~~ ~~DO~~ ~~NOT~~ ~~APPLY~~

~~(I)~~ ~~A~~ ~~BY,~~~~PHARMACY~~ ~~OWNED~~ ~~OR~~ ~~UNDER~~ ~~THE~~ ~~SAME~~ ~~CORPORATE~~
~~AFFILIATION,~~ ~~MANAGER;~~~~AS~~ ~~A~~ ~~PHARMACY~~ ~~BENEFITS~~ ~~OR~~

~~(II)~~ ~~A~~ ~~PHARMACY.~~~~MAIL~~ ~~ORDER~~

~~(F)~~ ~~THE~~ ~~§~~ ~~15–1632~~ ~~INSURANCE~~ ~~ARTICLE~~~~PROVISIONS~~ ~~OF~~ ~~OF~~ ~~THE~~ ~~APPLY~~ ~~TO~~
~~A~~ ~~MANAGED~~ ~~CARE~~ ~~ORGANIZATION~~ ~~THAT~~ ~~USES~~ ~~A~~ ~~PHARMACY~~ ~~BENEFITS~~ ~~MANAGER~~ ~~TO~~
~~MANAGE~~ ~~PRESCRIPTION~~ ~~DRUG~~ ~~COVERAGE~~ ~~BENEFITS~~ ~~ON~~ ~~BEHALF~~ ~~OF~~ ~~THE~~ ~~MANAGED~~
~~ORGANIZATION.~~~~CARE~~

~~Article~~ ~~–~~ ~~Insurance~~

~~15–1601.~~

– 2 –

PAGE 3
WES MOORE, Governor Ch. 217

~~(1)~~~~(s)~~ ~~“Purchaser”~~ ~~means~~ ~~a~~ ~~person~~ ~~that~~ ~~offers~~ ~~a~~ ~~plan~~ ~~or~~ ~~program~~ ~~in~~ ~~the~~ ~~State,~~
~~including~~ ~~the~~ ~~State~~ ~~Employee~~ ~~and~~ ~~Retiree~~ ~~Health~~ ~~and~~ ~~Welfare~~ ~~Benefits~~ ~~Program,~~ ~~AN~~
~~INSURER,~~ ~~PLAN,~~~~A~~ ~~NONPROFIT~~ ~~HEALTH~~ ~~SERVICE~~ ~~OR~~ ~~A~~ ~~HEALTH~~ ~~MAINTENANCE~~
~~ORGANIZATION,~~ ~~that:~~

~~[(1)]~~ ~~(I)~~ ~~provides~~ ~~prescription~~ ~~drug~~ ~~coverage~~ ~~or~~ ~~benefits~~ ~~in~~ ~~the~~ ~~State;~~ ~~and~~

~~[(2)]~~ ~~(II)~~ ~~enters~~ ~~into~~ ~~an~~ ~~agreement~~ ~~with~~ ~~a~~ ~~pharmacy~~ ~~benefits~~ ~~manager~~ ~~for~~
~~the~~ ~~provision~~ ~~of~~ ~~pharmacy~~ ~~benefits~~ ~~management~~ ~~services.~~

~~(2)~~ ~~“PURCHASER”~~ ~~DOES~~ ~~NOT~~ ~~INCLUDE~~ ~~A~~ ~~NONPROFIT~~ ~~HEALTH~~
~~THAT:~~~~MAINTENANCE~~ ~~ORGANIZATION~~

~~(I)~~ ~~MODEL;~~~~OPERATES~~ ~~AS~~ ~~A~~ ~~GROUP~~

~~(II)~~ ~~PROVIDES~~ ~~SERVICES~~ ~~SOLELY~~ ~~TO~~ ~~A~~ ~~MEMBER~~ ~~OR~~ ~~PATIENT~~ ~~OF~~
~~ORGANIZATION;~~~~THE~~ ~~NONPROFIT~~ ~~HEALTH~~ ~~MAINTENANCE~~ ~~AND~~

~~(III)~~ ~~FURNISHES~~ ~~SERVICES~~ ~~THROUGH~~ ~~THE~~ ~~INTERNAL~~ ~~PHARMACY~~
~~ORGANIZATION.~~~~OPERATIONS~~ ~~OF~~ ~~THE~~ ~~NONPROFIT~~ ~~HEALTH~~ ~~MAINTENANCE~~

~~15–1632.~~

~~A~~ ~~PHARMACY~~ ~~BENEFITS~~ ~~MANAGER~~ ~~THAT~~ ~~CONTRACTS~~ ~~WITH~~ ~~A~~ ~~PHARMACY~~ ~~ON~~
~~ORGANIZATION,~~ ~~§~~ ~~15–101~~~~BEHALF~~ ~~OF~~ ~~A~~ ~~MANAGED~~ ~~CARE~~ ~~AS~~ ~~DEFINED~~ ~~IN~~ ~~OF~~ ~~THE~~
~~HEALTH~~ ~~–~~ ~~GENERAL~~ ~~ARTICLE,~~ ~~SHALL~~ ~~REIMBURSE~~ ~~THE~~ ~~PHARMACY~~ ~~AN~~ ~~AMOUNT~~
~~NATIONAL~~ ~~AVERAGE~~ ~~DRUG~~ ~~ACQUISITION~~ ~~COST~~~~THAT~~ ~~IS~~ ~~AT~~ ~~LEAST~~ ~~EQUAL~~ ~~TO~~ ~~THE~~
~~FEE–FOR–SERVICE~~~~PLUS~~ ~~THE~~ ~~PROFESSIONAL~~ ~~DISPENSING~~ ~~FEE~~ ~~DETERMINED~~ ~~BY~~ ~~THE~~
~~MARYLAND~~ ~~DEPARTMENT~~ ~~HEALTH~~ ~~MARYLAND~~ ~~MEDICAL~~ ~~ASSISTANCE~~~~OF~~ ~~FOR~~ ~~THE~~
~~PROGRAM~~ ~~IN–STATE~~~~IN~~ ~~ACCORDANCE~~ ~~WITH~~ ~~THE~~ ~~MOST~~ ~~RECENT~~
~~COST–OF–DISPENSING~~ ~~SURVEY.~~

(a) The Maryland Department of Health and the Prescription Drug Affordability
Board jointly shall study:

(1) (i) the total amount the managed care organizations in the State
paid pharmacies for prescription drug claims in calendar years 2021 and 2022; and

(ii) what the total amount paid to pharmacies would have been, in
calendar years 2021 and 2022, if the prescription drug claims had been reimbursed at the
Maryland Medical Assistance Program fee–for–service rates; and

(2) how to best address the inconsistency in the amounts studied under
item (1) of this subsection by:
– 3 –

PAGE 4
Ch. 217 2023 LAWS OF MARYLAND

(i) considering the total cost to the State; and

(ii) recommending a methodology for determining the most accurate
ingredient cost of a drug and an appropriate dispensing fee.

(b) On or before October 31, 2023, the Maryland Department of Health and the
Prescription Drug Affordability Board jointly shall report its findings to the Maryland
Medicaid Administration and, in accordance with § 2–1257 of the State Government
Article, the Senate Budget and Taxation Committee, the Senate Finance Committee, the
House Appropriations Committee, and the House Health and Government Operations
Committee.

SECTION 2. AND BE IT FURTHER ENACTED, That this Act is an emergency
measure, is necessary for the immediate preservation of the public health or safety, has
been passed by a yea and nay vote supported by three–fifths of all the members elected to
each of the two Houses of the General Assembly, and shall take effect from the date it is
enacted.

Approved by the Governor, April 24, 2023.

– 4 –